Intestinal absorption characteristics of the low solubility thiocarboxanilide UC-781

被引:19
作者
Deferme, S
Van Gelder, J
Ingels, F
Van den Mooter, G
De Buck, S
Balzarini, J
Naesens, L
De Clereq, E
Kinget, R
Augustijns, P [1 ]
机构
[1] Katholieke Univ Leuven, Lab Pharmacotechnol & Biopharm, O&N, B-3000 Louvain, Belgium
[2] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
关键词
HIV; UC-781; NNRTI; Caco-2; vitamin E-TPGS; gelucire;
D O I
10.1016/S0378-5173(01)00952-8
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The aim of this study was to determine the intestinal absorption characteristics of the antiviral agent UC-781 and to optimize the experimental conditions of the in vitro system for low solubility compounds. The absorption potential of UC-781 was studied with the Caco-2 system and with the rat intestinal perfusion technique. The low solubility of UC-781 required the use of solubility/dissolution rate enhancing agents (e.g. VitE-TPGS, Gelucire 44/14). The creation of sink conditions in the receiver compartment of the Caco-2 system was a prerequisite to reliably study the transport of this poorly soluble compound. After inclusion of VitE-TPGS in the acceptor solution, UC-781 could be characterized as a class H drug of the Biopharmaceutical Classification System (low solubility, high permeation across membranes). A significant concentration-dependent decrease in transport of UC-781 was observed upon increasing the concentration of VitE-TPGS in the apical compartment. This observation contrasts to the absorption enhancing properties of VitE-TPGS, and can probably be attributed to a decrease in the concentration of free UC-781 when using higher concentrations of the solubility/dissolution rate enhancing agents. The use of Gelucire 44/14 as a solubilizing agent resulted in a batch-dependent degradation of UC-781. The inclusion of the solubility/dissolution rate-enhancing agent VitE-TPGS did not result in absorption enhancement in the intestinal perfusion technique. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:113 / 119
页数:7
相关论文
共 9 条
[1]   A THEORETICAL BASIS FOR A BIOPHARMACEUTIC DRUG CLASSIFICATION - THE CORRELATION OF IN-VITRO DRUG PRODUCT DISSOLUTION AND IN-VIVO BIOAVAILABILITY [J].
AMIDON, GL ;
LENNERNAS, H ;
SHAH, VP ;
CRISON, JR .
PHARMACEUTICAL RESEARCH, 1995, 12 (03) :413-420
[2]  
Annaert P, 2000, J PHARM SCI-US, V89, P1054, DOI 10.1002/1520-6017(200008)89:8<1054::AID-JPS10>3.0.CO
[3]  
2-5
[4]   The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds [J].
Aungst, BJ ;
Nguyen, NH ;
Bulgarelli, JP ;
Oates-Lenz, K .
PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1175-1180
[5]   Preclinical studies on thiocarboxanilide UC-781 as a virucidal agent [J].
Balzarini, J ;
Naesens, L ;
Verbeken, E ;
Laga, M ;
Van Damme, L ;
Parniak, M ;
Van Mellaert, L ;
Anné, J ;
De Clercq, E .
AIDS, 1998, 12 (10) :1129-1138
[6]   The thiocarboxanilides UC-10 and UC-781 have an additive inhibitory effect against human immunodeficiency virus type 1 reverse transcriptase and replication in cell culture when combined with Other antiretroviral drugs [J].
Balzarini, J ;
DeClercq, E .
ANTIVIRAL CHEMISTRY & CHEMOTHERAPY, 1997, 8 (03) :197-204
[7]   Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: Retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase [J].
Borkow, G ;
Barnard, J ;
Nguyen, TM ;
Belmonte, A ;
Wainberg, MA ;
Parniak, MA .
JOURNAL OF VIROLOGY, 1997, 71 (04) :3023-3030
[8]   The thiocarboxanilide nonnucleoside inhibitor UC781 restores antiviral activity of 3′-azido-3′-deoxythymidine (AZT) against AZT-resistant human immunodeficiency virus type 1 [J].
Borkow, G ;
Arion, D ;
Wainberg, MA ;
Parniak, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (02) :259-263
[9]   Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection [J].
De Clercq, E .
FARMACO, 1999, 54 (1-2) :26-45